About
Technology
Issues
FAQ
Links
Official Page
A phase II study of the efficacy and safety of the MET inhibitor capmatinib (INC280) in patients with advanced hepatocellular carcinoma
Distribution of the number of citations over years.
site/software ©
exaly
; All materials licenced under
CC by-SA
.